Pfizer's second quarter 2014 earnings of $0.58 per share were a
couple of cents above the Zacks Consensus Estimate and 4% above the
year-ago earnings. Revenues, which declined 2% to $12.8 billion,
were above the Zacks Consensus Estimate of $12.4 billion. Revenues
were impacted by the loss of exclusivity of certain products
including Detrol LA (in the U.S.), the expiry of the Spiriva
collaboration in some countries and the Enbrel agreement. Although
Pfizer maintained its guidance for 2014, the company cut its
revenue outlook. We believe revenues will remain under pressure
going forward. However, cost-cutting efforts and share buybacks
should help Pfizer achieve its earnings guidance. We remain Neutral
on the stock.
New York-based Pfizer, Inc. focuses on the development and
commercialization of a wide range of products including human and
animal biologic and small molecule medicines and vaccines, as well
as consumer health care products.
In Oct 2009, Pfizer acquired another large pharma company,
Wyeth, for $68 billion. With this acquisition, Pfizer became a more
diversified biopharma company with a stronger presence in emerging
markets. In Feb 2011, Pfizer acquired King Pharmaceuticals for $3.6
Pfizer conducts its commercial operations through three business
segments while two of these include Innovative business lines, the
third comprises the Value business line. One of the Innovative
segments (Global Innovative Pharmaceutical - GIP) includes products
that have patent protection beyond 2015 while the other focuses on
vaccines, oncology and consumer healthcare (Global Vaccines,
Oncology and Consumer Healthcare segment - VOC).
The Value segment (Global Established Pharmaceutical segment -
GEP) includes products generating strong and consistent cash flow.
Apart from including products that have lost market exclusivity,
mature, patent-protected products that are expected to lose
exclusivity through 2015 in most major markets are also a part of
this segment. Moreover, this segment includes biosimilars and
collaborations for established products like the company's
partnerships with Mylan in Japan, Teuto in Brazil and Hisun in
All three segments reflect the performance of developed as well
as emerging markets.
Important products in Pfizer's portfolio include Lyrica (for
several indications including the management of post-herpetic
neuralgia, diabetic peripheral neuropathy and fibromyalgia),
Prevnar (vaccine for the prevention of pneumococcal disease),
Sutent (advanced renal cell carcinoma), and Enbrel (rheumatoid
arthritis, juvenile rheumatoid arthritis, psoriatic arthritis,
plaque psoriasis and ankylosing spondylitis) among others.
In Nov 2012, Pfizer divested its Nutrition business to Nestl for
a cash consideration of $11.85 billion. In Aug 2011, Pfizer sold
its Capsugel unit to Kohlberg Kravis Roberts & Co L.P. for
$2.375 billion in cash. In Jun 2013, Pfizer gave up its stake in
its Animal Health business which was spun off in early 2013 and
started trading on NYSE from Feb 1, 2013 under the name Zoetis.
Pfizer reported worldwide sales of $51.6 billion in 2013 (down
6%). While sales from the Biopharmaceutical segment came in at
$47.9 billion, down 7%, Consumer Healthcare contributed $3.3
billion to 2013 sales, up 4%.
Pfizer Inc. (PFE): Read the Full Research
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.